(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 August 2022 (11.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/167607 A1

(51) International Patent Classification:
A61K 38/18 (2006.01) *A61P 27/02* (2006.01)

(21) International Application Number:
PCT/EP2022/052761

(22) International Filing Date:
04 February 2022 (04.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21155393.8 05 February 2021 (05.02.2021) EP

(71) Applicant: **DOMPE' FARMACEUTICI SPA** [IT/IT]; VIA SANTA LUCIA 6, 20121 MILANO (IT).

(72) Inventors: **ARAMINI, Andrea**; C/0 DOMPE' FARMACEUTICI SPA, Via Campo di Pile, snc, 67100 L'Aquila (IT). **AMENDOLA, Pier Giorgio**; c/o Dompé farmaceutici Spa, Via Tommaso De Amicis, 95, 80131 Napoli (IT). **SIRICO, Anna**; c/o Dompé farmaceutici Spa, Via Tommaso De Amicis, 95, 80131 Napoli (IT). **D'ANNIBALLE, Gaetano**; c/o Dompé farmaceutici Spa, Via Campo Pile, 67100 L'Aquila (IT). **CATTANI, Franca**; c/o Dompé farmaceutici Spa, Via Campo di Pile, 67100 L'Aquila (IT). **ALLEGRETTI, Marcello**; C/0 DOMPE' FARMACEUTICI SPA, Via Campo di Pile, snc, 67100 L'Aquila (IT). **MANTELLI, Flavio**; C/0 DOMPE' FARMACEUTICI SPA, Via Campo di Pile, snc, 67100 L'Aquila (IT).

(74) Agent: **MAURI, Elisabetta Maria Ester**; C/0 DOMPE' FARMACEUTICI SPA, VIA SANTA LUCIA 6, 20121 MILANO (IT).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES




FIG.11

(57) Abstract: The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of $p75^{NTR}$ is detrimental.

WO 2022/167607 A1

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*